Some Boston public school students are spending their summer vacations learning and working at a global biotech company.

A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggested big pharma may finally be willing to place ...

Frazier was among the most active venture investors in 2024, according to analysts at William Blair, backing 17 private life ...

Vertex Pharmaceuticals (VRTX) wrapped up July with a modest 0.16% uptick, signaling a cautious optimism in the stock market.

Detailed price information for Unitedhealth Group Inc (UNH-N) from The Globe and Mail including charting and trades.

U.S. equities rebounded strongly in Q2, with growth stocks and mid-caps leading gains; our portfolio outperformed via IT, ...

Franklin Templeton shares Q2 2025 results for ClearBridge All Cap Growth Portfolios: tech wins offset health care drag. See ...

Vertex Pharmaceuticals is making waves, popping up as one of the most searched stocks. Should you jump on the bandwagon?

Vertex Pharmaceuticals (VRTX) closed at $468.41 in the latest trading session, marking a +1.64% move from the prior day. This change outpaced the S&P 500's 0.3% loss on the day. Meanwhile, the Dow ...

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

VRTX eyes second-quarter growth with surging Trikafta sales. Investors' focus is likely to be on the progress of Casgevy, and ...

Held October 21 at 9OFS in Boston, this immersive experience is built for companies that know the future of performance is human-centered. With the s ...